Influence of heparin coating of coronary stents and ex vivo efficacy of different doses of acetylsalicylic acid and ticlopidine in a pulsed floating model of recirculating human plasma

Platelets

Volumn 13, Issue 8, 2002, Pages 443-449

  Brockmann, Marc A ^a   Gutensohn, Kai ^a   Bau, Juliane ^a   Kuehnl, Peter ^a   Meinertz, Thomas ^a   Nienaber, Christian ^b   Beythien, Christian ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; HEPARIN; PADGEM PROTEIN; SILICON; TICLOPIDINE; ANTICOAGULANT AGENT; BIOMATERIAL;

ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG COATING; DRUG EFFICACY; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOGENICITY; BIOLOGICAL MODEL; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; DRUG EFFECT; PHYSIOLOGY; REFERENCE VALUE; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

TOSCANA VIRUS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; COATED MATERIALS, BIOCOMPATIBLE; CORONARY VESSELS; HEPARIN; HUMANS; MALE; MODELS, CARDIOVASCULAR; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES; STENTS; TICLOPIDINE;

EID: 0036890915     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/0953710021000057802     Document Type: Article

References (35)

1. Ahn YK, et al. Preventive effects of the heparin-coated stent on restenosis in the porcine model. Catheter Cardiovasc Interv 1999; 48: 324-30.
2. Atalar E, et al. Effects of stent coating on platelets and endothelial cells after intracoronary stent implantation. Clin Cardiol 2001; 24: 159-64.
3. Berger PB, Dzavik V, Penn IM, Catellier D, Buller CE. Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). Am Heart J 2001; 142: 776-81.
4. Beythien C, et al. Influence of stent length and heparin coating on platelet activation: A flow cytometric analysis in a pulsed floating model. Thromb Res 1999; 94: 79-86.
5. Bhatt DL, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14.
6. Bossavy JP, et al. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998; 92: 1518-25.
7. De Scheerder I, et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997; 95: 1549-53.
8. Del Maschio A, Dejana E, Bazzoni G. Bidirectional modulation of platelet and polymorphonuclear leukocyte activities. Ann Hematol 1993; 67: 23-31.
9. Descotes J, Choquet-Kastylevsky G. Gell and Coombs's classification: Is it still valid? Toxicology 2001; 158: 43-9.
10. Fischman DL, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. New Engl J Med 1994; 331: 496-501.
11. Gehman S. Increased risk of restenosis after placement of gold-coated stents. Circulation 2001; 104: E23.
12. Gent M, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; i: 1215-20.
13. Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins, and platelets. Thromb Haemost 1988; 59: 1-6.
14. Gutensohn K, et al. In vitro analyses of diamond-like carbon coated stents. Reduction of metal ion release, platelet activation, and thrombogenicity. Thromb Res 2000; 99: 577-85.
15. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75: 550-4.
16. Hardhammar PA, et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996; 93: 423-30.
17. Hirsh J. Progress review: The relationship between dose of aspirin, side-effects and antithrombotic effectiveness. Stroke 1985; 16: 1-4.
18. Inoue T, et al. Early detection of platelet activation after coronary angioplasty. Coron Artery Dis 1996; 7: 529-34.
19. Itoh T, Nakai K, Ono M, Hiramori K. Can the risk for acute cardiac events in acute coronary syndrome be indicated by platelet membrane activation marker P-selectin? Coron Artery Dis 1995; 6: 645-50.
20. Kastrati A, et al. Increased risk of restenosis after placement of gold-coated stents: Results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation 2000; 101: 2478-83.
21. Kupfer, Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura. New Engl J Med 1997; 337: 1245.
22. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992; 86: III47-52.
23. Mak KH, Belli G, Ellis SG, Moliterno DJ. Subacute stent thrombosis: Evolving issues and current concepts. J Am Coll Cardiol 1994; 494-503.
24. McEver RP, Martin MN. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J Biol Chem 1984; 259: 9799-804.
25. Moussa I, et al. Subacute stent thrombosis and the anticoagulation controversy: Changes in drug therapy, operator technique, and the impact of intravascular ultrasound. Am J Cardiol 1996; 78: 13-7.
26. Nara W, Ashley I, Rosner F. Thrombotic thrombocytopenic purpura associated with clopidogrel administration: Case report and brief review. Am J Med Sci 2001; 322: 170-2.
27. Reichenberger F, Wirtz H, Paschke R. Clopidogrel and side effects. Cardiology 2001; 96: 51-2.
28. Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-62.
29. Schomig A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. New Engl J Med 1996; 334: 1084-9.
30. Serruys PW, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. New Engl J Med 1994; 331: 489-95.
31. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001; 104: 539-43.
32. Truong KM, Amankwa K, Kucukarslan S. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: A review. Clin Ther 2001; 23: 1145-65; discussion 1129.
33. Tschoepe D, et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
34. Whetsel TR, Bell DM. Rash in patients receiving ticlopidine after intracoronary stent placement. Pharmacotherapy 1999; 19: 228-31.
35. Windecker S, et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001; 104: 928-33.